Posted by Michael Wonder on 14 Jan 2019
Samsung faces resistance from big pharma in the U.S.
11 January 2019 - Incumbent biologic drug makers use rebates and exclusive contracts to fend off competition from new entrants.
Samsung’s foray into the U.S. biologic-drug market is proving tougher than expected in the face of strong resistance from established pharmaceutical companies.
Christopher Ko, the chief executive of the South Korean conglomerate’s drug-development arm, said in an interview that its biosimilars, or cheaper versions of branded biologic drugs, have faced an uphill climb unseating incumbents in the U.S., even though those companies’ main patents are expiring.
